With paltusotine, we’re developing a once-daily pill for acromegaly that may replace the life-disrupting process of getting an injection every month or needing to follow a strict daily schedule for short-acting octreotide. Soon entering Phase 3, a once-daily oral therapy will be a welcome development for patients and could solve for a real market need. And there’s plenty more where that came from. Read on for our latest advancements and the market opportunities they hold for investment in our focused area of endocrinology pharmaceuticals.

Press Releases


Crinetics Pharmaceuticals to Participate in December Investor Conferences

Crinetics management, including Dr. Scott Struthers and Dr. Alan Krasner, will participate in the upcoming Evercore ISI 3rd Annual HealthCONx Conference and the Piper Sandler 32nd Annual Healthcare Conference in December.

Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology

Peter Trainer, MD, FRCPE, a global leader in the endocrine community and expert in diseases of the pituitary and adrenal glands, joins Crinetics as Vice President of Clinical Endocrinology. 

Corporate Presentation

Change
Volume
Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Contact


Material Selections
Country

Contact


Material Selections
Country